Literature DB >> 20737192

Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.

Ki-Young Choi1, Tae-Young Jung, Shin Jung, Young-Hee Kim, Kyung-Sub Moon, In-Young Kim, Sam-Suk Kang, Kyung-Hwa Lee.   

Abstract

Oligodendroglial tumors sometimes show heterogeneous ring enhancement with a central necrotic portion. We aimed to reveal the prognosis of such tumors based on such radiologic findings and compare them to other prognostic factors. Participants were 32 patients with oligodendroglioma (17 oligodendrogliomas, 15 anaplastic oligodendrogliomas) who underwent surgery from 2004 to 2008. We investigated tumor radiologic findings, locations, calcification, whether localized or diffuse type, and enhancement patterns. Of other prognostic factors, we analyzed age, sex, pathology, extent of removal, adjuvant therapy, genetic change in 1p and 19q, and MGMT methylation status. We checked for genetic abnormality in 1p and 19q using the FISH method. To investigate MGMT methylation, we performed methylation-specific PCR (MSP). Mean follow-up duration was 3.2 years. Median age was 42.4 years, and the male:female ratio was 21:11. Out of 17 oligodendrogliomas, 14 (82.4%) showed combined 1p/19q deletion, and 14 (82.4%), methylated MGMT. Among 15 anaplastic oligodendrogliomas, there were 7 (46.6%) with combined 1p/19q deletion and 11 (73.3%) with methylated MGMT. The 4-year recurrence-free survival and overall survival were 77.6 and 100% in oligodendrogliomas and 59.1 and 71.6% in anaplastic oligodendrogliomas, respectively. On univariate analysis, radiologic variable of ring enhancement pattern was statistically significant related with recurrence-free survival (P = 0.003). Variables such as sex (P = 0.03), combined 1p/19q loss (P = 0.04), tumor location (P = 0.02), and anaplastic pathology (P = 0.04) were significantly correlated with overall survival. Cox's regression model revealed that ring enhancement pattern was associated with frequent recurrence (ring enhancement, hazard ratio = 8.281, P = 0.04), and these showed 1p deletion only. Anaplastic oligodendrogliomas with ring enhancement like glioblastomas and without combined 1p/19q loss should receive close follow-up after treatment because of frequent recurrences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20737192     DOI: 10.1007/s11060-010-0353-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

Review 1.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

Authors:  Martin van den Bent; Olivier-Louis Chinot; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

2.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.

Authors:  J S Smith; B Alderete; Y Minn; T J Borell; A Perry; G Mohapatra; S M Hosek; D Kimmel; J O'Fallon; A Yates; B G Feuerstein; P C Burger; B W Scheithauer; R B Jenkins
Journal:  Oncogene       Date:  1999-07-15       Impact factor: 9.867

4.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

Review 5.  Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Authors:  Guido Reifenberger; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

6.  Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article.

Authors:  Hamdy El-Hateer; Luis Souhami; David Roberge; Rolando Del Maestro; Richard Leblanc; Eman Eldebawy; Thierry Muanza; Denis Melançon; Petr Kavan; Marie-Christine Guiot
Journal:  J Neurosurg       Date:  2009-08       Impact factor: 5.115

7.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

Review 8.  Oligodendrogliomas.

Authors:  D Margain; P Peretti-Viton; A M Perez-Castillo; P Martini; G Salamon
Journal:  J Neuroradiol       Date:  1991       Impact factor: 3.447

9.  Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Caterina Giannini; Peter C Burger; Brian A Berkey; J Gregory Cairncross; Robert B Jenkins; Minesh Mehta; Walter J Curran; Ken Aldape
Journal:  Brain Pathol       Date:  2008-03-26       Impact factor: 6.508

10.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

View more
  1 in total

1.  Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology.

Authors:  Tae-Young Jung; Ji Yeoun Lee; Dong-Seok Kim; Hyeon Jin Park; Chae-Yong Kim; Young-Shin Ra; Mee-Jeong Lee; Seong-Ho Kim; Hee-Jo Baek; Il Han Kim; Kyung Duk Park; Seung-Ki Kim
Journal:  J Neurooncol       Date:  2014-11-04       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.